Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin- releasing hormone receptor antagonist in healthy women with normal ovulation.

Slides:

Advertisements

Similar presentations

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Advertisements

Subchorionic hematomas are increased in early pregnancy in women taking low-dose aspirin Ashley Truong, B.S., M. Mercedes Sayago, M.D., William H. Kutteh,

Impact of chemotherapeutics and advanced testicular cancer or Hodgkin lymphoma on sperm deoxyribonucleic acid integrity Cristian O'Flaherty, Ph.D., Barbara.

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study Jeff G. Wang, M.D., Richard A. Anderson,

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Male contraception Fertility and Sterility

Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Follicular and endocrine response to anastrozole versus clomiphene citrate administered in follicular phase to normoovulatory women: a randomized comparison

Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary.

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

A comparison of blood spot vs

Potential diagnostic utility of intermittent administration of short-acting gonadotropin- releasing hormone agonist in gonadotropin deficiency Carrie.

Occurrence of postmenopausal-like acidic follicle-stimulating hormone (FSH) isoforms precedes the rise of FSH before menopause Chris M.G. Thomas, Ph.D.,

The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility Alexander M. Quaas, M.D.,

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular.

Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized.

Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic.

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens

Robert F. Casper, M.D. Fertility and Sterility

A prospective randomized noninferiority study comparing recombinant FSH and highly purified menotropin in intrauterine insemination cycles in couples.

Anastrozole vs. clomiphene citrate in infertile women with ovulatory dysfunction: a phase II, randomized, dose-finding study Donald Tredway, M.D., Ph.D.,

Prokineticin 1, homeobox A10, and progesterone receptor messenger ribonucleic acid expression in primary cultures of endometrial stromal cells isolated.

Subchorionic hematomas are increased in early pregnancy in women taking low-dose aspirin Ashley Truong, B.S., M. Mercedes Sayago, M.D., William H. Kutteh,

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

René Ecochard, M. D. Ph. D. , Agnes Guillerm, M. D. , René Leiva, M. D

Andrew C. Bjonnes, M.S., Richa Saxena, Ph.D., Corrine K. Welt, M.D.

Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis Francesca Moro, M.D., Clara De Simone,

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS) F. Gonzalez,

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Effect of letrozole at 2. 5 mg or 5

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Increased secretion of amylin in women with polycystic ovary syndrome

Follicular loss in endoscopic surgery for ovarian endometriosis: quantitative and qualitative observations Daniela Romualdi, M.D., Ph.D., Gian Franco.

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Symptoms of premenstrual syndrome may be caused by hyperventilation

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D.,

Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D

Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial Antoni J. Duleba, M.D.,

Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Prokineticin 1 mRNA expression in the endometrium of healthy women and in the eutopic endometrium of women with endometriosis Federica Tiberi, B.S.,

Paolo Moghetti, M.D. Fertility and Sterility

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome:

Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with.

Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome Yuwen Wu, M.D., Jianhua Zhang,

Inappropriate gonadotropin secretion in polycystic ovary syndrome

Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D

Ronald M. Yang, M. D. , Richard A. Fefferman, M. D. , Charles E

A new era in ovulation induction

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef.

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated.

Presentation transcript:

Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin- releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase Francesca Sagnella, M.D., Rosanna Apa, M.D., Maurizio Guido, M.D., Paola Villa, M.D., Valentina Spadoni, M.D., Fiorella Miceli, M.D., Antonio Lanzone, M.D. Fertility and Sterility Volume 91, Issue 5, Pages 1857-1863 (May 2009) DOI: 10.1016/j.fertnstert.2008.02.120 Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 1 (a) FSH plasma levels in PCOS and in control group at each time studied; values are expressed as mean ± SD. (b) LH plasma levels in PCOS and in control group at each time studied; values are expressed as mean ± SD. (c) T plasma levels in PCOS and in control group; values are expressed as percentage in respect to the baseline to which a value of 100 is assigned. Statistical differences are calculated between PCOS and control groups at each studied point. Statistical analysis was performed using ANOVA followed by the Wilcoxon-Mann-Whitney test for comparison of data derived from two groups (each one made up of 10 women). Values with P<.05 were considered statistically significant. CTR = control. Fertility and Sterility 2009 91, 1857-1863DOI: (10.1016/j.fertnstert.2008.02.120) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Follicle-stimulating hormone, LH, A, T, 17-OH-P, and E2 sAUC during treatment in PCOS and control groups. Values are calculated as indicated in Materials and Methods section. Statistical analysis was performed with use of ANOVA followed by the Wilcoxon–Mann-Whitney test for comparison of data derived from two groups (each one made up of 10 women). Values with P<.05 were considered statistically significant. CTR = control. Fertility and Sterility 2009 91, 1857-1863DOI: (10.1016/j.fertnstert.2008.02.120) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions